Literature DB >> 20554358

Comparison of facial nerve injury and recovery rates after antegrade and retrograde nerve dissection in parotid surgery for benign disease: prospective study over 4 years.

Barry O'Regan1, Girish Bharadwaj.   

Abstract

The facial nerve can be dissected using an antegrade or retrograde approach. Antegrade dissection is the established technique and retrograde dissection is used less often. Recent publications have drawn attention to the potential value of the retrograde technique particularly if direct identification of the nerve trunk is difficult, and in revision procedures. We prospectively studied 43 consecutive procedures in 40 patients who had parotidectomy over a 4-year period, and evaluated and compared rates of temporary and permanent nerve injury, and nerve recovery after antegrade and retrograde dissection in operations for benign parotid disease. Each patient was allocated randomly to the antegrade (n=20) or retrograde (n=20) groups. Three patients were excluded. All patients had peroperative nerve monitoring and were followed up at 1 week, 1 month, 3 months, or to full recovery of the nerve. The House-Brackmann (HB) grading system was used to assess the degree of injury to the nerve. A high rate of serious nerve injury (HBIII or above) was associated with retrograde dissection at 1 week. Serious nerve injuries (HBIII or above) were slow to recover after the antegrade technique at 3 months. There was no difference between groups in the rates of full nerve recovery at 6 months.
Copyright © 2010 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20554358     DOI: 10.1016/j.bjoms.2010.05.013

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  8 in total

Review 1.  Review of surgical techniques and guide for decision making in the treatment of benign parotid tumors.

Authors:  Georgios Psychogios; Christopher Bohr; Jannis Constantinidis; Martin Canis; Vincent Vander Poorten; Jan Plzak; Andreas Knopf; Christian Betz; Orlando Guntinas-Lichius; Johannes Zenk
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-04       Impact factor: 2.503

Review 2.  Antero- vs. retrograde nerve dissection in parotidectomy: a systematic review and meta-analysis.

Authors:  Petar Stankovic; Jan Wittlinger; Nina Timmesfeld; Stephan Hoch Stephan; Robert Georgiew; Thomas Günzel; Afshin Teymoortash; Thomas Wilhelm
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-20       Impact factor: 2.503

3.  Identification of facial nerve displaced vertically in locally invasive mucoepidermoid carcinoma of parotid gland: A rare case discussion.

Authors:  Harsha Mp; Karan Padha
Journal:  J Oral Biol Craniofac Res       Date:  2022-06-28

Review 4.  Parotid surgery for benign tumours.

Authors:  Farzad Borumandi; Katherine S George; Luke Cascarini
Journal:  Oral Maxillofac Surg       Date:  2012-07-31

5.  New Treatment in Facial Nerve Palsy Caused by Sagittal Split Ramus Osteotomy of Mandible.

Authors:  Jin Hoon Lee; Kyung Ah Lee
Journal:  Arch Craniofac Surg       Date:  2017-03-25

6.  Intramasseteric schwannoma treated with facelift incision and retrograde facial nerve dissection.

Authors:  Jae Ha Hwang; Dong Gyu Lee; Ho Seup Sim; Kwang Seog Kim; Sam Yong Lee
Journal:  Arch Craniofac Surg       Date:  2019-12-20

7.  Indications for partial superficial parotidectomy for benign parotid gland tumors using the retrograde approach.

Authors:  Masahiro Suzuki; Yuta Nakaegawa; Tetsuro Kobayashi; Tomotaka Kawase; Masakazu Ikeda; Shigeyuki Murono
Journal:  Fukushima J Med Sci       Date:  2020-06-05

8.  Antegrade versus retrograde facial nerve dissection in benign parotid surgery: Is there a difference in postoperative outcomes? A meta-analysis.

Authors:  Mubarak Ahmed Mashrah; Taghrid Ahmed Al-Dhohrah; Fahmi Ahmed Al-Zubeiry; Lingjian Yan; Faez Saleh Al-Hamed; Xiaopeng Zhao; Chaobin Pan
Journal:  PLoS One       Date:  2018-10-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.